Article: New data support Hepsera's long-term efficacy against chronic hepatitis B.

Article: FDA Approves Gilead's Hepsera(TM) for the Treatment of ...
PR Newswire;  September 23, 2002 ;     700+ words ... ... clinical studies, Hepsera treatment was associated ... chronic hepatitis B. Hepsera is the first drug ... patients in a 48-week double-blind, placebo ... with resistance to Hepsera have not been identified through 48 weeks of treatment in pivotal ...

Article: FDA Approves Gilead's Hepsera for the Treatment of Chronic ...
Business Wire;  September 20, 2002 ;     700+ words ... ... clinical studies, Hepsera treatment was associated ... chronic hepatitis B. Hepsera is the first drug ... patients in a 48-week double-blind, placebo ... with resistance to Hepsera have not been identified through 48 weeks of treatment in pivotal ...

Article: New Data Support Hepsera's Long-Term Efficacy against ...
Business Wire;  April 15, 2004 ;     700+ words ... ... percent after 96 weeks. The median ... levels among Hepsera-treated ... copies/mL at week 144. Hepsera also provided ... through 144 weeks, as measured ... baseline by week 144. All ... continuing Hepsera therapy and ... through 144 weeks. Probability ...

Article: 96-Week Data Show Hepsera Reduces Liver Damage and ...
Business Wire;  April 9, 2003 ;     700+ words ... ... from the first 48 weeks of the study were ... Medicine. The 48-week results demonstrated ... that therapy with Hepsera was associated ... Following the first 48 weeks of treatment ... treatment over 96 weeks, 71 percent of ... DNA levels among Hepsera-treated patients ... copies/mL at ...

Article: Gilead Sciences' Hepatitis B Drug Hepsera Approved for ...
Business Wire;  March 11, 2003 ;     700+ words ... ... Clinical Studies of Hepsera Two placebo-controlled ... studies have evaluated Hepsera in a wide range of patients ... hepatitis B. The 48-week results from these two ... treatment in the first 48 weeks of therapy with Hepsera were asthenia (weakness ...

Article: Gilead Announces 144-Week Data of Hepsera in ...
Business Wire;  October 28, 2003 ;     700+ words ... ... open-label study of Hepsera in chronic hepatitis ... initiating treatment with Hepsera. The median baseline ... TM) Monitor PCR). Hepsera was associated with a ... DNA levels after 144 weeks of treatment: -5 ... less than 0.001) at week 144, compared with ...

Article: Results of Two Pivotal Studies of Gilead's Hepsera ...
Business Wire;  February 27, 2003 ;     700+ words ... ... infected persons. At 48 weeks, twice as many patients who received Hepsera had decreased liver inflammation ... among patients who took Hepsera daily beyond 48 weeks. According to Kaplan ... interim data, 75 percent of Hepsera patients had normalized ...